A new survey by Deutsche Bank shows the vast majority of Amazon Prime members with health insurance would be willing to purchase prescription drugs from the retailer's website—suggesting that Amazon could significantly reshape the pharmacy landscape if it chooses to enter the mail-order pharmaceutical market.
Coca-Cola is exploring the cannabis-infused beverage market with an eye toward creating a "functional wellness beverage"—but it's unclear whether such a product would be legal in the United States, and medical professionals caution that cannabidiol's (CBD) purported wellness benefits are largely unproven.
The global clinical research review entity Cochrane last week voted to expel a board member who has been outspoken against the pharmaceutical industry—prompting four members to resign in protest a week before the group's annual gathering in Edinburgh.
The direct-to-consumer genetic testing market 'is a regulatory Wild West,' Laura Hercher, a genetic counselor, writes in a New York Times opinion piece. But as 32-year-old New York City resident Matt Fender learned firsthand, genetic tests from different companies can show conflicting results, leaving patients 'to grapple with the discordant results' on their own.
When actuaries detected a slowdown in Medicare spending growth a few years ago, Medicare officials claimed it was a one-time blip due to the recession. But one expert is spearheading research that paints a different picture—revealing a sustained slowdown in spending that the larger health care system could learn from, Politico's Dan Diamond reports.
New research is helping hospitals find superbugs in places providers hadn't previously thought to clean. Here are the unexpected places where germs are turning up—and how three hospitals are fighting them, Lucette Lagnado reports for the Wall Street Journal.